[Periodic fever syndrome associated with mutations in the TNF type 1 receptor gene: A differential diagnosis of familial Mediterranean fever that should not be overlooked in patients of Mediterranean origin].

Le syndrome de fièvre prolongée associée aux mutations du gène du récepteur au TNF de type 1 : un diagnostic différentiel de la fièvre méditerranéenne familiale à ne pas méconnaître chez les patients d’origine méditerranéenne.
Autoinflammatory disease Familial Mediterranean fever Fièvre méditerranéenne familiale Fièvre récurrente héréditaire Hereditary recurrent fever Maladie auto-inflammatoire Syndrome périodique associé aux mutations du récepteur du facteur de nécrose tumorale de type 1 (TRAPS) TNFRSF1A TRAPS

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 29 06 2020
revised: 23 08 2020
accepted: 30 08 2020
pubmed: 3 11 2020
medline: 25 11 2021
entrez: 2 11 2020
Statut: ppublish

Résumé

Tumor Necrosis Factor Type 1 Receptor Associated Periodic Syndrome (TRAPS) is a rare autosomal dominant autosomal autoinflammatory disease associated with mutations in the TNF type 1 receptor gene (TNFRSF1A). It is characterized by relatively long recurrent febrile seizures with an average duration of 7 days accompanied by arthralgia, myalgia, and usually a rash. In a patient of Mediterranean origin with recurrent fever, familial Mediterranean fever is the first diagnosis to be suspected by argument of frequency. A retrospective observational study was conducted on patients from Mediterranean origin followed for TRAPS and included in the "Juvenile Inflammatory Rheumatism" (JIR) observational cohort in the national French autoinflammatory center. The age of onset of symptoms, age of diagnosis, number of years of wandering and treatments received were collected for each index case. Nine patients from 6 families of Mediterranean origin were included. A molecular diagnosis confirmed TRAPS in all patients. The median age at diagnosis was 26 years, the mean number of years of wandering was 17 years. The diagnosis of FMF was made first in all patients. AA amyloidosis revealed TRAPS in 2 patients. Colchicine was started without any efficacy in all cases. Five patients were treated with interleukin-1 inhibitory biotherapy with 100% efficacy. In a patient of Mediterranean origin presenting with recurrent febrile abdominal pain of AA amyloidosis, the first diagnosis to be suspected is FMF. Long relapses, dominant transmission, a non-Mediterranean relative, and the ineffectiveness of colchicine should evoke TRAPS.

Identifiants

pubmed: 33131906
pii: S0248-8663(20)30353-2
doi: 10.1016/j.revmed.2020.08.007
pii:
doi:

Substances chimiques

Receptors, Tumor Necrosis Factor, Type I 0
TNFRSF1A protein, human 0

Types de publication

Journal Article Observational Study

Langues

fre

Sous-ensembles de citation

IM

Pagination

459-464

Informations de copyright

Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

R Bourguiba (R)

Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France.

L Savey (L)

Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France.

A Aouba (A)

Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France.

S Deshayes (S)

Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France.

O Fain (O)

Service de médecine interne, Sorbonne université, hôpital Saint-Antoine, AP-HP, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France.

N Martin-Silva (N)

Service de médecine interne, Unicaen, CHU de Caen Normandie, Normandie université, 14000 Caen, France.

V Hentgen (V)

Service de pédiatrie générale, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), hôpital André-Mignot, Versailles, France.

A Desdoits (A)

Service de pédiatrie générale, CHU de Caen Normandie, 14000 Caen, France.

G Grateau (G)

Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France.

I Giurgea (I)

Laboratoire de génétique médicale, Inserm U933, Sorbonne université, hôpital Trousseau, Paris, France.

S Georgin-Lavialle (S)

Service de médecine interne, centre de référence des maladies auto-inflammatoires et des amyloses d'origine inflammatoire (CEREMAIA), Sorbonne université, hôpital Tenon, AP-HP, 20, rue de la Chine, 75020 Paris, France. Electronic address: sophie.georgin-lavialle@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH